Zum Inhalt springen
Sponsorship
Die MVF-Knowledge-HubsFrisch aus der Forschung. Täglich aktualisiert!

Suchen Sie in Hunderten nationaler und internationaler Datenbanken nach dem neuesten Studienwissen der angegebenen Themengebiete und/oder lassen Sie sich werktäglich per Newsletter informieren. Die Newsfeeds werden auf deutsch übersetzt and nach Übertragbarkeit auf das deutsche Gesundheits-/Versorgungssystem ausgewählt:

Zu den Knowledge-Hubs

Slowed down? New antidiabetics in Germany

Diabetes mellitus often has serious and long-term consequences for those affected, both in terms of health and economics. It's not just the medically complex complications of the metabolic disease that affect the quality of life of patients. Drug therapy, which is usually necessary for life, also requires a high level of long-term adherence on the part of the patient. In addition, the approval of new active ingredients always raises the question of whether existing therapy needs to be reviewed and possibly adjusted. The present analysis shows new developments in the antidiabetics market and compares innovative and existing drugs, also taking the AMNOG (Medicines Market Reorganization Act) into account.

Read more
First publication date: 16.10.2014

Plain Text

>> Across Germany, around 7.3 percent of the adult population suffers from diabetes mellitus. The prevalence is less than 2 percent in people under 45 years of age, but increases significantly with age (see GBE compact, 3/2011 or GEDA 2009; overall prevalence for types 1 and 2). However, estimates of the prevalence of diabetes mellitus in Germany and forecasts of growth rates vary depending on the source. If it is assumed that around 6 million people with diabetes live in Germany, it can be assumed that caring for those suffering from diabetes is associated with high health costs. For 2008, the Federal Statistical Office estimated the direct costs of caring for people with diabetes at 6.3 billion euros. This corresponds to a share of 2.5 percent of health expenditure for all diseases - and the trend is rising (GBE compact, 3/2011).
Depending on the individual clinical picture, the extent and type of symptoms as well as the risks of secondary diseases, the therapy differs from patient to patient. At its core, however, it consists of regulating blood sugar levels through antidiabetic drugs.

....

Citation information: doi: 10.24945/MVF.06.14.1866-0533.1967

... subscribers can find the detailed interview in archive

Do you want to leave us already?

Subscribe to our newsletter quickly. Then you can be sure that you won't miss anything.